PGE 5949404
Latest Information Update: 28 Aug 2002
Price :
$50 *
At a glance
- Originator Procter & Gamble
- Class
- Mechanism of Action Cell wall inhibitors; DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Feb 1999 New profile
- 16 Feb 1999 Preclinical development for Bacterial infections in USA (Unknown route)